Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.52 |
| ▸ | CHRNB4 known ✓ | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 known ✓ | P32297 | 2/20 | 0.31 |
| ▸ | SAT1 | P21673 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL431350 | 1.00 | SAT1 (0.57) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL10004983 | 0.98 | SAT1 (0.59) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL18721523 | 0.98 | SAT1 (0.59) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL15884118 | 0.98 | SAT1 (0.59) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL12085581 | 0.98 | SAT1 (0.59) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL5066404 | 0.93 | SAT1 (0.54) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL14001877 | 0.93 | SAT1 (0.54) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL15884023 | 0.93 | SAT1 (0.54) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL12085585 | 0.93 | SAT1 (0.54) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL12951342 | 0.93 | SAT1 (0.54) | SAT1CYP2C19MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937235-A2 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | Pathologica, LLC. (US) | 2008-07-02 | — | — | EP | claimed |
| US-20070078187-A1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA, LLC. (US) | 2007-04-05 | — | — | US | claimed |
| WO-2007035957-A2 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA, LLC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-7087648-B1 | Methods for modulating macrophage proliferation using polyamine analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-08 | — | — | US | claimed |
| US-20050159493-A1 | Methods for modulating macrophage proliferation using polyamine analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-07-21 | — | — | US | claimed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-2665471-B1 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG | PATHOLOGICA LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-3228310-A1 | METHYLGLYOXAL BIS(GUANYL-HYDRAZONE) FOR REGULATING OSTEOPONTIN IN A SUBJECT | Pathologica LLC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2121586-B1 | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS | PATHOLOGICA LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1937235-B1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-1444520-A2 | METHODS FOR MONITORING AMYOTROPHIC LATERAL SCLEROSIS | SLIL Biomedical Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030175832-A1 | Methods for monitoring and treating amyotrophic lateral sclerosis | PATHOLOGICA, LLC | 2003-09-18 | — | — | US | disclosed |
| WO-2003048773-A2 | METHODS FOR MONITORING AMYOTROPHIC LATERAL SCLEROSIS | SLIL BIOMEDICAL CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6392098-B1 | ANTICANCER AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-05-21 | — | — | US | disclosed |
| EP-0934249-B1 | CONFORMATIONALLY RESTRICTED POLYAMINES AND THEIR USE AS ANTINEOPLASTIC AGENTS | WISCONSIN ALUMNI RES FOUND (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1027040-A2 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS | The Regents of the University of California (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021542-A2 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5889061-A | ANTICANCER, ANTITUMOR AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078187-A1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | GLS, SHMT2, ARG2 | GLA 366/4885CHRNB4 4825/4885CHRNA3 4852/4885 |
| US-20050159493-A1 | Methods for modulating macrophage proliferation using polyamine analogs | ARG1, MKI67, CSF1R | GLA 833/4885CHRNB4 2840/4885CHRNA3 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.